1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Iptcaopan 200 mg: new trials by email Literature Review of Iptcaopan 200 mg trials Research Report on Iptcaopan 200 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS Iptcaopan 200 mg - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 65 | 2024-05-08 | 2026-06-04 |
Atypical Hemolytic Uremic Syndrome (1) · Glomerulonephritis, Membranoproliferative (1) · Thrombotic Microangiopathies (1)
Brazil (1) · China (1) · Czechia (1) · India (1) · Japan (1) · Turkey (Türkiye) (1)